Claims for Patent: 12,115,143

Summary for Patent: 12,115,143

Title:	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:	Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):	Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François DUBUISSON
Assignee:	Flamel Ireland Ltd
Application Number:	US18/537,342
Patent Claims:	1. A pharmaceutical formulation comprising: an immediate release portion comprising gamma-hydroxybutyrate; a modified release portion comprising particles, the particles comprising gamma-hydroxybutyrate and a coating, wherein the coating comprises a methacrylic acid and methyl methacrylate copolymer and a methacrylic acid and ethyl acrylate copolymer; an acidifying agent; and one or more suspending or viscosifying agents, wherein the formulation comprises an amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate, and wherein the acidifying agent and the one or more suspending or viscosifying agents are not a component of the particles. 2. The pharmaceutical formulation of claim 1, wherein the formulation is designed to be administered orally only once nightly. 3. The pharmaceutical formulation of claim 1, wherein the modified release portion comprises hydrogenated vegetable oil. 4. The pharmaceutical formulation of claim 1, wherein the suspending or viscosifying agents comprise 1% to 15% (w/w) of the formulation. 5. The pharmaceutical formulation of claim 1, wherein the suspending or viscosifying agents comprise 2% to 10% (w/w) of the formulation. 6. The pharmaceutical formulation of claim 1, wherein the suspending or viscosifying agents comprise 2% to 5% (w/w) of the formulation. 7. The pharmaceutical formulation of claim 1, wherein the suspending or viscosifying agents comprise 2% to 3% (w/w) of the formulation. 8. The pharmaceutical formulation of claim 1, wherein the acidifying agent is selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, benzoic acid, and mixtures thereof, and wherein the one or more suspending or viscosifying agents is selected from the group consisting of xanthan gum, medium viscosity sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and guar gum, medium viscosity hydroxyethyl cellulose, agar, sodium alginate, mixtures of sodium alginate and calcium alginate, gellan gum, carrageenan gum grade iota, kappa or lambda, medium viscosity hydroxypropylmethyl cellulose, and mixtures thereof. 9. The pharmaceutical formulation of claim 1, wherein the coating is 10 to 50% of the weight of the particles. 10. The pharmaceutical formulation of claim 1, wherein the coating is 15 to 45% of the weight of the particles. 11. The pharmaceutical formulation of claim 1, wherein the coating is 20 to 40% of the weight of the particles. 12. The pharmaceutical formulation of claim 1, wherein the coating is 25 to 35% of the weight of the particles. 13. The pharmaceutical formulation of claim 1, wherein the coating is 30% of the weight of the particles. 14. A pharmaceutical formulation comprising: an immediate release portion comprising gamma-hydroxybutyrate; a modified release portion comprising particles, the particles comprising gamma-hydroxybutyrate and a coating, wherein the coating comprises a methacrylic acid and methyl methacrylate copolymer, and a methacrylic acid and ethyl acrylate copolymer; an acidifying agent selected from the group consisting of malic acid, tartaric acid, and mixtures thereof; and a suspending or viscosifying agent comprising at least one of carrageenan gum, hydroxyethyl cellulose or xanthan gum, wherein the acidifying agent and the suspending or viscosifying agent are separate and distinct from the particles. 15. A pharmaceutical formulation comprising: an immediate release portion comprising gamma-hydroxybutyrate; a modified release portion comprising particles, the particles comprising gamma-hydroxybutyrate and a coating, wherein the coating comprises a methacrylic acid and methyl methacrylate copolymer, and a methacrylic acid and ethyl acrylate copolymer; an acidifying agent comprising 1.2% to 15% (w/w) of the formulation; and one or more suspending or viscosifying agents selected from the group consisting of xanthan gum, sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and guar gum, hydroxyethyl cellulose, agar, sodium alginate, mixtures of sodium alginate and calcium alginate, gellan gum, carrageenan gum, hydroxypropylmethyl cellulose, and mixtures thereof, wherein the acidifying agent and the one or more suspending or viscosifying agents are separate and distinct from the particles. 16. The pharmaceutical formulation of claim 15, wherein the acidifying agent comprises 1.2% to 10% (w/w) of the formulation. 17. The pharmaceutical formulation of claim 15, wherein the acidifying agent comprises 1.2% to 5% (w/w) of the formulation. 18. The pharmaceutical formulation of claim 15, wherein the acidifying agent comprises 1.6% to 3.2% (w/w) of the formulation. 19. The pharmaceutical formulation of claim 15, wherein the acidifying agent comprises about 1.6% (w/w) of the formulation. 20. The pharmaceutical formulation of claim 15, wherein the acidifying agent is selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, benzoic acid, and mixtures thereof. 21. The pharmaceutical formulation of claim 15, wherein the acidifying agent comprises malic acid. 22. The pharmaceutical formulation of claim 15, wherein the acidifying agent consists of malic acid. 23. The pharmaceutical formulation of claim 15, wherein the acidifying agent comprises tartaric acid. 24. The pharmaceutical formulation of claim 15, wherein the acidifying agent consists of tartaric acid. 25. The pharmaceutical formulation of claim 15, wherein the one or more suspending or viscosifying agents comprises at least one of carrageenan gum, hydroxyethyl cellulose, or xanthan gum. 26. A pharmaceutical formulation comprising: an immediate release portion comprising gamma-hydroxybutyrate; and a modified release portion comprising particles, the particles comprising gamma-hydroxybutyrate and a coating, wherein the coating comprises: a polymer carrying free carboxylic groups and having a pH trigger of from 5.5 to 6.97; and a hydrophobic compound having a melting point equal or greater than 40° C., wherein a weight ratio of the hydrophobic compound to the polymer carrying free carboxylic groups is from 0.4 to 4; an acidifying agent; and one or more suspending or viscosifying agents, wherein the acidifying agent and the one or more suspending or viscosifying agents are not a component of the particles.